

HATAY PHARMACEUTICAL JOINT STOCK COMPANY
REVIEWED INTERIM SEPARATE
FINANCIAL STATEMENTS

For the period from January 01, 2025 to June 30, 2025



No.: 620/CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, August 25, 2025

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company

Stock Code: DHT

Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City

Phone: 0433 501 117 – Fax: 0433 829 054

Information disclosure officer: Mr. Ngo Van Chinh – Head of the Supervisory Board

In the Separate Financial Statements for the first six months of 2025, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax for the first six months of 2025 was VND 28,612,987,213, compared to VND 34,327,930,350 for the same period in 2024, representing a decrease of VND 5,714,943,137, equivalent to a 16.65% decline, mainly due to:

- General and administrative expenses for the first six months of 2025 were VND 57,414,106,905, compared to VND 46,353,637,140 for the same period in 2024, an increase of VND 11,060,469,765, equivalent to 23.86%.
- Finance costs for the first six months of 2025 were VND 13,245,813,064, compared to VND 11,625,076,116 for the same period in 2024, an increase of VND 1,620,736,948, equivalent to 13.94%, mainly due to foreign exchange rate fluctuations during the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:

- As above
- Archive: Office files

**HA TAY PHARMACEUTICAL JOINT STOCK
COMPANY**

General Director



TỔNG GIÁM ĐỐC
DS. Lê Xuân Chưởng

TABLE OF CONTENTS

CONTENTS	PAGE
BOARD OF MANAGEMENT'S REPORT	2 - 3
REVIEW REPORT ON INTERIM FINANCIAL INFORMATION	4
INTERIM SEPARATE BALANCE SHEET	5 - 6
INTERIM SEPARATE INCOME STATEMENT	7
INTERIM SEPARATE CASH FLOW STATEMENT	8 - 9
NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS	10 - 38

BOARD OF MANAGEMENT'S REPORT

We, members of Board of Management of Hatay Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") present this Report together with the Company's reviewed Interim Consolidated Financial Statements for the period from January 01, 2025 to June 30, 2025.

The Board of Directors and the Board of Management

Member of the Board of Directors and the Board of Management who held the Company during the period from January 01, 2025 to June 30, 2025 and to the date of this report, include:

The Board of Directors

Mr. Le Van Lo	Chairman
Mr. Le Anh Trung	Vice Chairman
Ms. Le Viet Linh	Member
Mr. Le Xuan Thang	Member
Mr. Hoang Van Tue	Member
Mr. Hiroyasu Nishioka	Member
Mr. Keisuke Oshio	Member

The Board of Management

Mr. Le Xuan Thang	General Director
Mr. Nguyen Ba Lai	Deputy General Director
Mr. Le Anh Trung	Deputy General Director
Ms. Le Viet Linh	Deputy General Director
Mr. Ngo Tuan Viet	Deputy General Director

Respective responsibilities of Board of Management

Board of Management of the Company is responsible for preparing Interim Separate Financial Statements which give a true and fair view of the financial position, business operation results and cash flows of the Company in the period, in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Separate Financial Statements. In the preparation of these Interim Separate Financial Statements, Board of Management is required to:

- Select suitable accounting policies and then consistently apply them;
- Make judgments and estimates that are reasonable and prudent;
- State whether appropriate accounting standards are respected or any application of material misstatements needs to be disclosed and justified in Interim Separate Financial Statements;
- Prepare the Interim Separate Financial Statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business; and
- Design and implement an effective internal control system for the purpose of properly preparing and presenting the Interim Separate Financial Statements so as to minimize risks and frauds.

BOARD OF MANAGEMENT'S REPORT

(continued)

Board of Management is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and that the Interim Separate Financial Statements comply with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Separate Financial Statements. Board of Management is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

Board of Management confirms that the Company has complied with the above requirements in preparing these Interim Separate Financial Statements.

For and on behalf of Board of Management,

HATAY PHARMACEUTICAL JOINT STOCK COMPANY



Le Xuan Thang
General Director
Hanoi, August 19, 2025



Hanoi, August 22, 2025

**To: The Shareholders
The Board of Management and Board of Directors
Hatay Pharmaceutical Joint Stock Company**

Respective responsibilities of Board of Management

Board of Management of the Company is responsible for the preparation and true & fair presentation of the Interim Separate Financial Statements of Company in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations relating to the preparation and presentation of the Interim Separate Financial Statements and for such internal control as Board of Management determines is necessary to enable the presentation of Interim Separate Financial Statements that are free from material misstatements whether due to fraud or error.

Respective responsibilities of Auditor

Our responsibility is to express a conclusion on the accompanying Interim Separate Financial Statements based on our review. We conducted our review in accordance with Vietnamese Standard on Review Engagement (VSRE) 2410 – Review of Interim Financial Information Performed by the Independent Auditor of the Entity.

A review of Interim Separate Financial Statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Vietnamese Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's conclusion

Base on our review, nothing has come to our attention that causes us to believe that the accompanying Interim Separate Financial Statements do not present fairly, in all material respects, the separate financial position of the Company as at June 30, 2025, and of its financial performance and its cash flows for the period then ended in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations related to the preparation and presentation of Interim Separate Financial Statements.



Nguyen Thi Hong Van
Deputy General Director – Audit Director
Audit Practising Registration Certificate No. 0946-2023-034-1
For and on behalf of
VIETNAM AUDITING AND EVALUATION CO., LTD

Form B 01a - DN

INTERIM SEPARATE BALANCE SHEET

As at June 30, 2025

Unit: VND

ASSETS	Codes	Notes	30/6/2025	01/01/2025
A - CURRENT ASSETS	100		932,364,910,928	878,083,877,890
I. Cash and cash equivalents	110	V.1.	138,239,257,205	69,332,546,815
1. Cash	111		58,239,257,205	49,332,546,815
2. Cash equivalents	112		80,000,000,000	20,000,000,000
II. Short-term financial investments	120		60,000,000,000	90,000,000,000
1. Held-to-maturity investments	123	V.2.	60,000,000,000	90,000,000,000
III. Short-term receivables	130		202,805,658,550	194,274,305,948
1. Short-term trade accounts receivable	131	V.3.	130,634,237,671	130,260,462,165
2. Advances to suppliers	132	V.4.	67,261,365,621	58,456,628,765
3. Other short-term receivables	136	V.5.	8,434,055,981	8,868,366,252
4. Provision for short-term doubtful debts	137		(3,524,000,723)	(3,311,151,234)
IV. Inventories	140	V.7.	527,077,127,293	500,275,955,440
1. Inventories	141		529,038,177,044	502,237,005,191
2. Provision for devaluation of inventories	149		(1,961,049,751)	(1,961,049,751)
V. Other current assets	150		4,242,867,880	24,201,069,687
1. Value added tax deductibles	152		3,620,012,051	23,569,800,473
2. Taxes and other receivables from the Stage budget	154	V.14.	622,855,829	631,269,214
B - NON-CURRENT ASSETS	200		1,010,971,794,310	991,993,422,748
I. Other long-term receivables	210		-	-
II. Fixed assets	220		168,932,618,027	171,359,140,731
1. Tangible fixed assets	221	V.11.	167,555,958,027	169,982,480,731
- Historical cost	222		396,204,089,393	390,168,870,525
- Accumulated depreciation	223		(228,648,131,366)	(220,186,389,794)
2. Intangible fixed assets	227	V.8.	1,376,660,000	1,376,660,000
- Historical cost	228		2,026,660,000	2,026,660,000
- Accumulated amortization	229		(650,000,000)	(650,000,000)
III. Long-term assets in progress	240		811,773,951,785	790,109,801,102
1. Work in progress	242	V.9.	811,773,951,785	790,109,801,102
IV. Long-term financial investments	250	V.2.	25,893,525,000	25,893,525,000
1. Investment into subsidiaries	251		22,743,525,000	22,743,525,000
2. Investments into joint-venture, associates	252		3,150,000,000	3,150,000,000
V. Other non-current assets	260		4,371,699,498	4,630,955,915
1. Long-term prepayment expenses	261	V.10.	4,371,699,498	4,630,955,915
TOTAL ASSETS (270 = 100 + 200)	270		1,943,336,705,238	1,870,077,300,638

(Notes from page 10 to page 38 are an integral part of these Interim Separate Financial Statements)

Form B 01a - DN

INTERIM SEPARATE BALANCE SHEET

As at June 30, 2025
(continued)

RESOURCES		Codes	Notes	30/6/2025	Unit: VND 01/01/2025
C - LIABILITIES		300		897,125,941,720	852,479,524,333
I. Current liabilities		310		795,845,686,248	751,163,268,861
1. Short-term trade accounts payable		311	V.12.	297,064,872,740	223,336,294,360
2. Short-term advances from customers		312	V.13.	150,088,373,148	130,401,909,109
3. Taxes and payables to the State budget		313	V.14.	2,944,368,519	5,620,857,096
4. Payables to employees		314		13,616,892,472	14,679,425,689
5. Short-term accrued expenses		315	V.15.	2,126,531,079	162,743,579
6. Unearned short-term revenue		318	V.16.	1,497,365,896	909,298,387
7. Other short-term payables		319	V.17.	287,431,378	72,107,933
Short-term loans and obligations under finance lease		320	V.18.	325,692,156,052	373,273,974,867
9. Welfare and bonus fund		322		2,527,694,964	2,706,657,841
II. Non-current liabilities		330		101,280,255,472	101,316,255,472
1. Other long-term payables		337	V.17.	4,367,300,000	4,403,300,000
Long-term loans and obligations under finance lease		338	V.18.	96,912,955,472	96,912,955,472
D - OWNER'S EQUITY		400		1,046,210,763,518	1,017,597,776,305
I. Owner's equity		410	V.19.	1,046,210,763,518	1,017,597,776,305
1. Owner's contributed capital		411		823,417,730,000	823,417,730,000
- Ordinary shares with voting right		411a		823,417,730,000	823,417,730,000
2. Share premium		412		96,320,000,000	96,320,000,000
3. Other capital		414		24,375,893,101	24,375,893,101
4. Treasury stock		415		(15,130,000)	(15,130,000)
5. Investment and development fund		418		8,963,148,976	8,963,148,976
6. Retained earnings		421		93,149,121,441	64,536,134,228
- Retained earnings accumulated to the prior year end		421a		64,536,134,228	38,143,074,892
- Retained earnings of this period		421b		28,612,987,213	26,393,059,336
II. Other resources and funds		430		-	-
TOTAL RESOURCES (440=300 + 400)		440		1,943,336,705,238	1,870,077,300,638

Prepared by

Nguyen Thi Bich Ngoc

Chief Accountant

Hoang Van Tue

General Director



Le Xuan Thang

(Notes from page 10 to page 38 are an integral part of these Interim Separate Financial Statements)

Form B 02a - DN

INTERIM SEPARATE INCOME STATEMENT

For the period from January 01, 2025 to June 30, 2025

Unit: VND

ITEMS	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
1 Gross revenue from goods sold and services rendered	01	VI.1.	1,015,603,390,628	934,184,288,263
2 Deductions	02	VI.2.	-	136,570,760
3 Net revenue from goods sold and services rendered (10=01-02)	10	VI.3.	1,015,603,390,628	934,047,717,503
4 Cost of sales	11	VI.4.	915,306,801,744	842,559,235,151
5 Gross profit from goods sold and services rendered (20=10-11)	20		100,296,588,884	91,488,482,352
6 Financial income	21	VI.5.	12,917,918,262	15,074,335,766
7 Financial expenses	22	VI.6.	13,245,813,064	11,625,076,116
In which: Interest expense	23		7,127,225,787	6,415,974,512
8 Selling expenses	25	VI.9.	13,939,566,132	14,301,659,202
9 General and administration expenses	26	VI.9.	57,414,106,905	46,353,637,140
10 Operating profit (30=20+(21-22)-(25+26))	30		28,615,021,045	34,282,445,660
11 Other income	31	VI.7.	7,444,508,390	7,095,590,238
12 Other expenses	32	VI.8.	629,444,489	3,616,523
13 Profit from other activities (40 = 31 - 32)	40		6,815,063,901	7,091,973,715
14 Accounting profit before tax (50=30+ 40)	50		35,430,084,946	41,374,419,375
15 Current corporate income tax expenses	51	VI.11.	6,817,097,733	7,046,489,025
16 Deferred corporate income tax expenses	52		-	-
17 Net profit after corporate income tax (60=50-51-52)	60		28,612,987,213	34,327,930,350

Hanoi, August 19, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by



Nguyen Thi Bich Ngoc

Chief Accountant



Hoang Van Tue

General Director



Le Xuan Thang

(Notes from page 10 to page 38 are an integral part of these Interim Separate Financial Statements)

INTERIM SEPARATE CASH FLOW STATEMENT

(Under indirect method)

For the period from January 01, 2025 to June 30, 2025

ITEMS	Codes	Notes	Unit: VND	
			From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
I. Cash flow from operating activities				
1. Profit before tax	01		35,430,084,946	41,374,419,375
2. Adjustments for				
- Depreciation of fixed assets and investment properties	02		10,873,955,699	8,272,662,442
- Provisions	03		212,849,489	1,652,903,450
- Foreign exchange loss/gain arising from translating foreign currency items	04		5,299,727,203	1,192,027,911
- Gain, loss from investing activities	05		(5,072,975,261)	(10,636,044,582)
- Interest expense	06		7,127,225,787	6,415,974,512
3. Profit from operating activities before changes in working capital	08		53,870,867,863	48,271,943,108
- Increases/Decreases in receivables	09		10,903,558,912	51,273,394,801
- Increases/Decreases in inventories	10		(26,801,171,853)	(44,826,452,288)
- Increases/Decreases in payables (excluding interest payable, corporate income tax payable)	11		98,501,284,046	11,631,187,205
- Increases/Decreases in prepayment expense	12		259,256,417	358,495,842
- Interest expense paid	14		(7,173,238,312)	(6,482,210,439)
- Corporate income tax paid	15		(8,736,787,583)	(6,409,662,633)
- Other cash outflows	17		(178,962,877)	(199,700,000)
Net cash flow from operating activities	20		120,644,806,613	53,616,995,596
II. Cash flow from investing activities				
1. Acquisition and construction of fixed assets and other non-current assets	21		(39,531,937,520)	(68,730,881,964)
2. Proceeds from sale, disposal of fixed assets and other non-current assets	22		100,000,000	-
3. Cash outflows for lending, buying debt instruments of other entities	23		(60,000,000,000)	(140,000,000,000)
4. Cash recovered from lending, selling debt instruments of other entities	24		90,000,000,000	100,000,000,000
5. Interest earned, dividends and profits received	27		5,275,002,680	9,087,551,483
Net cash flow from investment activities	30		(4,156,934,840)	(99,643,330,481)
III. Cash flow from financial activities				
1. Proceeds from borrowing	33		381,263,054,367	324,607,532,614
2. Repayment of borrowing	34		(428,844,873,182)	(452,036,704,645)
3. Dividends and profits paid	36		-	(41,170,130,000)
Net cash flow from financial activities	40		(47,581,818,815)	(168,599,302,031)

(Notes from page 10 to page 38 are an integral part of these Interim Separate Financial Statements)

INTERIM SEPARATE CASH FLOW STATEMENT

(Under indirect method)

For the period from January 01, 2025 to June 30, 2025

(continued)

Unit: VND

ITEMS	Codes	Notes	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
Net cash flow in the period (50 = 20+30+40)	50		68,906,052,958	(214,625,636,916)
Cash and cash equivalents at the beginning of the period	60		69,332,546,815	282,314,872,903
Effect of changes in foreign exchange rates	61		657,432	874,354
Cash and cash equivalents at the end of the period (70 = 50+60+61)	70	V.01	138,239,257,205	67,690,110,341


Hanoi, August 19, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by

Chief Accountant

General Director



Nguyen Thi Bich Ngoc



Hoang Van Tue



Le Xuan Thang

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

I. Operational characteristics of enterprise

1. Structure of ownership

Hatay Pharmaceutical Joint Stock Company (hereinafter referred to as "Company") is a Joint Stock Company converted from a State-owned enterprise in accordance with Decision No. 1911/QĐ/UB dated 21/12/2000 of the People's Committee of Ha Tay province (now the People's Committee of Hanoi city). The company operates under the first Business Registration Certificate No. 030300015 dated 10/01/2001 issued by Ha Tay province Authority for Planning and Investment (now the Hanoi Authority for Planning and Investment). The company has changed its Business Registration Certificate 24 times.

According to the 24th amended Business Registration Certificate No. 0500391400 dated 15/01/2024 issued by Hanoi Authority for Planning and Investment, the charter capital is **VND 823,417,730,000** (*Eight hundred twenty three billion, four hundred seventeen million, seven hundred thirty thousand Vietnamese Dong./.*).

Shares of the Company are listed on the Hanoi Stock Exchange (HNX) under securities code of DHT.

2. Business domain

The principal activities of the company are to manufacturing and trading of medicines, services.

3. Business lines

- Manufacture of pharmaceuticals, medicinal chemical and botanical products. Details: Medicine manufacturing enterprise; Production of pharmaceuticals, medicinal materials, cosmetics, medicinal foods and medical equipment; Retailing of medicine, medical instruments, cosmetics and hygiene items in specialized stores. Details: Implement the right to distribute medicine and raw materials for making medicine produced by the facility in Vietnam;
- Wholesale of other household articles. Details: Implementing the right to distribute, wholesale goods according to the provisions of law (excluding goods on the list of national reserves and rice, cane sugar, beet sugar, cigarettes and cigars, crude oil and processed oil, explosives, books and magazines, precious metals and precious stones, recorded items on all materials);
- Implementing the right to wholesale medicine and pharmaceutical ingredients produced by the facility itself in Vietnam; Selling medicine and pharmaceutical ingredients to medicine and pharmaceutical ingredient sales facilities according to Clause 10, Article 91 of Decree No. 54/2017/ND-CP;
- Trading of own or rented property and land use rights. Details: Real estate business (Not including investment in building infrastructure for cemeteries and graveyards to transfer land use rights associated with infrastructure);
- Other remaining business support service activities n.e.c.. Details: Medicine storage service; Exercising the right to import and export goods according to the provisions of the Law (excluding goods on the national reserve list and goods in Appendix No. 1 and Appendix No. 2 of Circular 34/2013/TT-BCT); Implementing the right to import and export medicine and pharmaceutical ingredients;
- Manufacture of other food products n.e.c. Details: Production of functional foods; Wholesale of foods. Details: Implementation of the right to distribute and wholesale goods according to the provisions of law (excluding goods on the national reserve list and rice, cane sugar, beet sugar)/.

The Company's Head Office: No. 10A Quang Trung, Ha Dong, Hanoi.

4. Normal course of production and business

An ordinary course of business operations of the Company lasts no more than 12 months.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

5. Structure of enterprise

List of accounting and reporting units of the Company

- | | | |
|--|---|---|
| 1. Pharmaceutical Branch No. 1 | - | Address: 4th floor, 10A Quang Trung, Ha Dong ward, Hanoi, Vietnam |
| 2. Branch of Hatay Pharmaceutical Joint Stock Company in Nghe An | - | Address: No. 80, Nguyen Trai street, Vinh Phu ward, Nghe An province, Vietnam |
| 3. Ba Vi Pharmaceutical Branch | - | Address: No. 406, Quang Oai street, Quang Oai commune, Hanoi, Vietnam |
| 4. Thuong Tin Pharmaceutical Branch | - | Address: No. 251 Ga street, Thuong Tin Commune, Hanoi, Vietnam |
| 5. My Duc Pharmaceutical Branch | - | Address: No. 92, Team 3, Te Tieu Village, My Duc Commune, Hanoi, Vietnam |
| 6. Dan Phuong Pharmaceutical Branch | - | Address: House No. 2, Street 422, Zone 6, Hoai Duc commune, Hanoi, Vietnam |
| 7. Branch of Hatay Pharmaceutical Joint Stock Company in Thai Binh | - | Address: Lot 13, Group 22, Doc Den Street, Resettlement Area, Tran Lam Ward, Hung Yen Province, Vietnam |
| 8. Phu Xuyen Pharmaceutical Branch | - | Address: My Lam sub-area, Phu Xuyen commune, Hanoi city, Vietnam |
| 9. Son Tay Pharmaceutical Branch | - | Address: No. 122, Le Loi, Son Tay Ward, Hanoi, Vietnam |
| 10. Quoc Oai Pharmaceutical Branch | - | Address: Pho Huyen street, Quoc Oai commune, Hanoi, Vietnam |
| 11. Ung Hoa Pharmaceutical Branch | - | Address: No. 96, Hong Phong hamlet, Hoang Xa village, Van Dinh commune, Hanoi, Vietnam |
| 12. Thanh Oai Pharmaceutical Branch | - | Address: No. 121, Kim Bai Street, Thanh Oai commune, Hanoi, Vietnam |
| 13. Thach That Pharmaceutical Branch | - | Address: Road 84, Thach That commune, Hanoi, Vietnam |
| 14. Branch of Hatay Pharmaceutical Joint Stock Company | - | Address: 4th Floor, No. 10A Quang Trung, Ha Dong ward, Hanoi, Vietnam |

List of the Company's subsidiaries under direct control

Company only invests in 01 subsidiary is Ha Tay Pharmaceutical and Medical Equipment Joint Stock Company, headquartered at No. 10, Alley 4, Xom Street, Phu Luong ward, Hanoi, Vietnam. The principal activities of this subsidiary are the production of functional foods and trading of medical equipment. At the end of the accounting period, the Company's capital contribution ratio in the subsidiary is 50.63%, the voting rights ratio and the benefit ratio are equivalent to the capital contribution ratio.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

List of the Company's associates

Company name	Head quarter	Main operating activities	Proportion of contribution	Voting right proportion
1. Southern Hataphar Company Limited.	No. 62 Tran Van Giap Street, Phu Thanh ward, Ho Chi Minh City, Vietnam	Trading in medical machines, equipment and instruments.	48.28%	48.28%
2. Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company.	No. 80A Quang Trung Street, Ha Dong ward, Hanoi, Vietnam	Pharmaceutical business and distribution.	49%	49%

6. Comparability of information on the Interim Separate Financial Statements

Comparative figures are the figures of Company's Interim Separate Financial Statements of the Company for the period from January 01, 2025 to June 30, 2025.

7. Employees

The number of the employees as at June 30, 2025 is 585 people (as at December 31, 2024: 780 people).

II. Accounting period, currency used in accounting

1. Accounting period

The Company's accounting period begins on 01/01 and ends on 31/12 every year.

These Interim Separate Financial Statements are prepared for the period from January 1, 2025 to June 30, 2025.

2. Currency used in accounting

The currency used in accounting is Vietnam dong ("VND") accounted under the principle of historical cost, in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and the legal regulations related to the preparation and presentation of Interim Separate Financial Statements.

III. Applied accounting regime and standards

1. Applied accounting regime and standards

The Company applies the Accounting regime for enterprises promulgated under the Circular No. 200/2014/TT-BTC dated 22/12/2014 by Ministry of Finance guiding the accounting regime for enterprises and Circular No. 53/2016/TT-BTC dated 21/3/2016 by Ministry of Finance regarding amendment to some articles of Circular No. 200/2014/TT-BTC.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

2. Statement on the compliance to Accounting Standards and Accounting regime

The Company's Interim Separate Financial Statements are prepared and presented in accordance with current Vietnamese Accounting Standards and Vietnamese Accounting regime for enterprises and relevant legal regulations to the preparation and presentation of the Interim Separate Financial Statements.

IV. Significant accounting policies

1. Basis of preparing the Interim Separate Financial Statements

These Interim Separate Financial Statements are separate ones prepared for the Parent Company. The Company prepares these Interim Separate Financial Statements with a view to disclosing information, in particular, in accordance with regulations in the Circular No. 96/2020/TT-BTC dated 16/11/2020 by Ministry of Finance guiding information disclosure on stock exchange market. In addition, the Company also prepares Interim Consolidated Financial Statements for the Company and Subsidiaries (as presented in details in Note I.5.) for the 6 month period ended June 30, 2025 and in accordance with Vietnamese Accounting Standards, Vietnamese Accounting regime for enterprises and legal regulations related to the preparation and presentation of Interim Consolidated Financial Statements.

Users of these Interim Separate Financial Statements should read these reports together with the Interim Consolidated Financial Statements for full view over the interim consolidated financial position, interim consolidated income statement and interim consolidated cash flows of the Company.

2. Estimates

The preparation of Interim Separate Financial Statements in conformity with Vietnamese Accounting Standards, accounting regime for enterprises and legal regulations relating to financial reporting requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the Interim Separate Financial Statements and the reported amounts of revenues and expenses during the financial period. Although these accounting estimates are based on the management's best knowledge, actual results may differ from those estimates.

3. Principle for recognizing Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, demand deposits, short-term investments (not non exceed 3 months), highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

4. Accounting principle for financial investments

Held-to-maturity investments

Held-to maturity investments consist of investment amounts that the Company intends and is able to hold to the maturity date. Held-to-maturity investments include: term bank deposits.

Held-to maturity investments are recognized starting from the acquisition date and initial value of such held-to-maturity investments are determined under purchase price and expenses related to transactions of purchasing investment amounts. Interest proceeds from held-to-maturity investments after purchase date are recognized on the Income Statement on the basis of estimates. Interest before the Company holds the investments shall be deducted from historical cost at purchase time.

Held-to-maturity investments are measured at cost less provision for doubtful debts.

Provision for doubtful debts of investments held to maturity is appropriated in accordance with current accounting regulations.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Investment into subsidiaries

Subsidiaries are companies under control of the Company. The control means the Company is able to control financial policies and operations of investee companies in order to get economic benefits from these companies.

Investments into associates

An associate is an entity in which the Company has significant influence but not control over the financial and operating policies and that is neither a subsidiary nor a joint venture of the Company. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies.

Investments in subsidiaries and associates are initially recorded at cost, including the purchase price or capital contribution plus costs directly related to the investment. In case of investment in non-monetary assets, the cost of the investment is recorded at the fair value of the non-monetary assets at the time of arising.

Dividends and profits from periods prior to the investment being purchased are recorded as a reduction in the value of the investment itself. Dividends and profits from periods subsequent to the investment being purchased are recorded as revenue. Dividends received in shares are only recorded as the number of shares increased, not record the value of the shares received.

Provision for investments in subsidiaries and associates is appropriated at the time of preparing Separate Financial Statements when investments in subsidiaries and associates have decreased compared to original cost, the Company appropriated provisions as follows:

For investments whose fair value cannot be determined at the balance sheet date, provisions are appropriated at an amount equal to the difference between the actual capital contributions of the parties at the subsidiaries and associated companies and the actual equity multiplied by the Company's capital contribution ratio compared to the total actual capital contributions of the parties at the subsidiaries and associated companies.

Increase, decrease in the provision for investment in subsidiaries and associates companies that must be appropriated at the closing date of preparing Interim Separate Financial Statements is recorded in financial expenses.

As at June 30, 2025, the Company has no investments need to make provision.

5. Accounting principle of accounts receivable

Receivables are stated at book value less provision for doubtful debts.

Classification of receivables is made on the following principle:

- Trade accounts receivable consist of receivables with their commercial nature arising from transactions with their purchasing-selling nature between the Company and buyers who are independent entities from the Company, including receivables between parent company and its subsidiaries, associates.
- Other receivables consist of receivables with their non-commercial nature, not related to transactions with their purchasing-selling nature.

Provision for doubtful debts is made for each doubtful based on age of each debt amounts or estimated loss that may incur because debtors are insolvent under liquidation, bankruptcy or similar hardship.

Increase, decrease in provision for doubtful debts to be made at the accounting period end shall be recognized into general administration expenses.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

6. Principle for recognizing inventories

Inventories are recognized at the lower of cost and net realizable value. The cost of inventories consists of expenses of acquisition, processing and other directly related expenses incurred to bring inventories to their present location and condition.

Net realizable value is determined as the estimated selling price of inventories during the normal business period minus the estimated costs to complete and sell them.

Inventory value is calculated using the monthly weighted average method and accounting follow perpetual inventory.

Method of appropriated inventory devaluation provision: Inventory devaluation reserve is set up for each inventory item that has a decrease in value (original price is greater than net realizable value). Increases and decreases in inventory depreciation reserve balance that must be set up at the closing date of the interim separate financial statements are recorded in cost of goods sold.

7. Principle for fixed asset recognition and depreciation

Tangible fixed assets are recognized at their historical cost, presented in the Separate Balance Sheet under the items of historical cost, accumulated depreciation and carrying amount.

The historical cost of procured tangible fixed assets includes their purchase price (excluding trade discount or other discount), taxes and directly related costs to bring such assets into the ready-for-use state.

Historical cost of fixed assets which are constructed by contractors includes value of completed and handover works, directly-related costs and stamp duty.

The historical cost of procured tangible fixed assets include actual price of tangible fixed assets which are self-constructed or self-made and their installation and commissioning expense.

The expenses incurred after the initial recognition of tangible fixed assets are recorded as the increases of historical cost of assets when these expenses are sure to increase economic benefits in the future. The incurred expenses which do not satisfy the above conditions are recognized into operating expenses in the period.

The Company applied straight-line depreciation method to tangible fixed assets. Tangible fixed assets are accounted and classified into groups by their nature and purpose of utilization in the Company's production and business operation, including:

<i>Type of fixed assets</i>	<i>Depreciation duration <year></i>
- Land, building and architectural objects	06 - 25
- Machinery, equipment	06 - 10
- Means of transportation	07
- Managerial equipment, tools	03 - 06
- Others	04

Gains or losses from asset disposal or sale are differences between proceeds from disposal and carrying amount of the assets and recognized in the Interim Separate Income Statement.

8. Principle for intangible fixed asset recognition and amortization

Intangible fixed assets are recognized at their historical cost, presented in the Separate Balance Sheet under the items of historical cost, accumulated amortization and carrying amount.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Historical cost of acquired intangible fixed assets consists of their total purchase price to bring the assets to their state of ready-to-use. The costs arising after initial recognition of intangible fixed assets are recorded as production costs in the period excluding specific costs of a specific intangible asset, enabling an increase in the future economic benefits.

When an intangible fixed asset is sold or disposed, historical cost and accumulated amortization are written off and gain or loss from disposal is recognized into income or expense in the year.

Intangible assets of the Company include land use rights and software programs.

Land use rights

Land use rights are all actual costs that the Company has incurred that are directly related to the land use rights with indefinite at 62 Tran Van Giap, Phu Thanh ward, Ho Chi Minh City, Vietnam. Indefinite land use rights are not amortized under prevailing regulations.

Accounting software

Costs relating to accounting software programs that are not part of the related hardware are capitalized. Historical cost of accounting software is the total cost paid by the Company up to the date the software is put into use. Accounting software is amortized on a straight-line basis in 03 years.

9. Principle for recognizing cost of construction in progress

Properties in the course of construction for production, rental or administrative purposes, or for other purposes, are carried at cost that are necessary to form the assets in accordance with the Company's accounting policy. Depreciation of these assets, on the same basis as other assets, commences when the assets are ready for their intended use.

10. Principle for recognition and allocation of prepaid expenses

Prepaid expenses consist of actual expenses incurred but related to the business performance of many accounting periods. Prepaid expenses include: factory repair costs; tools, instruments issued for use awaiting for allocation and other others prepaid expenses.

Repair costs of factories represent major costs incurred periodically during the useful life of the assets. These costs are initially recorded at cost and are allocated to the income statement on a straight-line basis over a period not exceeding 3 years.

Tools, instruments issued for use awaiting for allocation and other others prepaid expenses are expected to bring future economic benefits to the Company. These expenses are capitalised as prepayments and are allocated to the Income Statement using the straight-line method over a period of not more than 3 years.

11. Accounting principle for liabilities

Liabilities are amounts payable to suppliers and other subjects. Liabilities comprise trade accounts payable and other payables. Liabilities are not recorded at lower amounts than payment obligation.

Classification of liabilities is made on the following principle:

- Trade accounts payable comprise of liabilities with their commercial nature arising from purchasing goods, services, assets and the suppliers are independent from buyers, including payables between parent company and its subsidiaries, associates.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS *(continued)*

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

- Other amounts payable comprise amounts payable with their non-commercial nature, not related to transactions of purchasing, selling and supplying goods, services.

Payables are followed in detail by each entity and payment term. Foreign currency payables are assessed by the Company at the selling exchange rate of the Vietnam Joint Stock Commercial Bank for Industry and Trade.

12. Principle for recognizing loans

Loans are recognized on the basis of receipts, bank vouchers, loan agreement and loan contracts.

Loans are monitored by details of each item, due date and original currency.

13. Principle for recognition and capitalization of borrowing costs

Borrowing costs consist of loan interest and other costs that incurs in direct connection with the borrowings.

Borrowing costs are recognized into operation and production costs in the year if arising, unless they are capitalized in accordance with Accounting Standard "Borrowing Costs". As a result, borrowing costs which directly relate to procurement, construction investment or production of properties that need a quite long period to be completed for putting into operation or business shall be plus in historical cost of property until such property would be put into use or business. The incomes arising from the temporary investment of loans are deducted from the historical cost of related assets. For a separate loan for the construction of fixed assets and investment property, borrowing cost is capitalized even if the construction period is less than 12 months.

14. Principle for recognizing accrued expense

The Company's accrued expenses include interest expenses and expenses for the Company's 60th anniversary, which are expenses in the reporting period but have not been paid due to non have invoices yet or insufficient accounting records and documents, and are recorded in the production and business expenses of the reporting period.

Accrued expenses on production and business expenses in the period are calculated strictly with reasonable and reliable evidence on the expenses to be accrued in the period to ensure the accounting expenses payable to be accounted will match the actual costs incurred.

15. Principle for recognizing unearned revenue

Unearned revenue includes revenue received in advance by customers for one or more accounting periods in terms of office lease, location.

16. Principle for recognizing owner's equity

Capital investment of the Company's owners is recognized by shareholders' actual capital contribution.

Share premium is recorded as the difference between the issue price and the par value of shares when first issued, additional issued, the difference between the reissue price and the book value of treasury stock and the equity component of convertible bonds at maturity. Direct costs related to the additional issuance of shares and reissue of treasury stock are recorded as a decrease in share premium.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Other capital is formed by supplementing from business results, revaluation of assets and the remaining value between the fair value of donated, presented, and sponsored assets after deducting taxes payable (if any) related to these assets.

Treasury stock are shares that the Company buys back from its own shares, the payment including transaction-related expenses, is recorded as treasury shares and reflected as a deduction in equity. When reissued, the difference between the reissue price and the book value of the treasury stock is recorded in the item "Share premium".

Retained earnings are the profit amounts from enterprise's business operation after deducting CIT expense this year.

Profit after corporate income tax is allocated to shareholders right after funds are made for under the Corporation Article of the Company as well as legal regulations and upon approval of the Annual General Meeting.

Dividends are recorded as liabilities when approved by the General Meeting of Shareholders.

According to the provisions of Clause 4, Article 34 of Decree 47/2021/ND-CP dated April 1, 2021 of the Government - Detailing a number of articles of the Law on Enterprises, Enterprises that have contributed capital, purchased shares before 01/7/2015 have the right to buy, sell, transfer, increase or decrease capital contributions and number of shares but must not increase the cross-ownership ratio compared to the time before 01/7/2015. The amount of capital contributed by a subsidiary to the Company is from before 01/7/2015 and also does not increase the existing cross-ownership ratio.

17. Principle and method of recognizing revenue, other income

Revenue of the Company includes revenue from goods sold, finished medicine, includes revenue from interest of bank deposits and dividends received.

Sales revenue

Revenue from selling goods is recognized upon simultaneously meeting the following five (5) conditions as follows:

- The Company has transferred the majority of risks and benefits associated with the right to own the products or goods to the buyer;
- The Company no longer holds the right to manage the goods as the goods owner, or the right to control the goods;
- Turnover is determined with relative certainty. In case the contract specifies that buyers have the right to return goods or products that were bought under specific terms, the revenue is only recognized when these specific terms no longer exist and the buyers have no right to return goods or products (except for the case that customers can return goods as exchange to other goods or services);
- The Company gained or will gain economic benefits from the sale transaction; and
- It is possible to determine the costs related to the goods sale transaction.

Interest income

Interest amounts are recognized on accrual basis, being determined on balances of deposits and actual interest rate in the period.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Paid dividend, shared profit

Paid dividend and shared profit are recognized when the Company has the right to receive dividends or profit from their contribution. Dividend received in shares is only recognized in number of additional shares, value of shares received/recorded is not recognized at par.

Other income of the Company is revenue from house rental, fixed asset liquidation, labor rental, training, business cooperation and other income, recorded on the basis of house rental contracts, fixed asset liquidation sale contracts, financial invoices, receipts, bank documents and related accounting documents.

18. Principle and method of recognizing financial expense

Financial expense recognized in Separate Income Statement is the total financial expense incurred in the period, without offset with revenue from financial income, including interest expenses, exchange rate difference.

19. Others

Tax liabilities

Value added tax (VAT)

The Company declares and calculates VAT under the guidelines of current value added tax law.

Corporate income tax

Corporate income tax presents the total amount of current tax payable.

Current tax payable is calculated on taxable profit in the year. Taxable income differs from net profit presented in the Separate Income Statement because taxable income does not include assessable incomes or expenses or deductible one in other years (including losses carried forward, if any) and it further excludes items that are non-taxable or non-deductible.

The Company applies corporate income tax rate at 20% on taxable profit.

The corporate income tax of the Company is determined in conformity with current tax regulations. However, these regulations may change from time to time and the final determination of corporate income tax will depend on the tax check results of competent tax authorities.

Other taxes

Other taxes and fees are declared and paid to the local tax authorities in compliance with the current regulations of the State.

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

V. Additional information of items presented in Interim Separate Balance Sheet**1. Cash and cash equivalents**

	30/6/2025	01/01/2025
	VND	VND
Cash	58,239,257,205	49,332,546,815
Cash on hand	4,764,499,696	6,304,273,376
Cash in bank	53,474,757,509	43,028,273,439
VND	53,357,533,439	42,795,836,641
USD	106,249,299	224,301,351
EUR	10,974,771	8,135,447
Cash equivalents (*)	80,000,000,000	20,000,000,000
Total	138,239,257,205	69,332,546,815

(*) Term deposit at Vietnam Joint Stock Commercial Bank for Industry and Trade with terms of less than 3 months.

2. Financial investments**a) Held-to-maturity investments**

	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Book value	Cost	Book value
Short-term	60,000,000,000	60,000,000,000	90,000,000,000	90,000,000,000
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	40,000,000,000	40,000,000,000	90,000,000,000	90,000,000,000
Vietnam Asia Commercial Joint Stock Bank - Ha Dong Branch (2)	20,000,000,000	20,000,000,000	-	-
Total	60,000,000,000	60,000,000,000	90,000,000,000	90,000,000,000

(1) Comprise: Term deposit No. 320/2024/65306 dated July 03, 2024 with maturity term of 6 months of VND 50 billion, interests rates 4.4% per year, interest payment at maturity and Term deposit No. 320/2024/65307 dated July 03, 2024 with maturity term of 6 months of VND 40 billion, interests rates 4.4% per year, interest payment at maturity. (These contracts were settled during the period.); and Term deposit No. 320/2025/9160 dated March 31, 2025 with maturity term of 6 months of VND 40 billion, interests rates 4.8%/year, interest payment at maturity.

(2) Term deposit No. 75/HDTG/VAB-DHT dated March 27, 2025 with maturity term of 6 months of VND 20 billion, interest payment at maturity.

b) Capital contribution into other entities

	30/6/2025		01/01/2025	
	VND		VND	
	Cost	Provision	Cost	Provision
Investment into subsidiaries	22,743,525,000	-	22,743,525,000	-
Hatay Pharmaceutical and Medical Equipment Joint Stock Company (i)	22,743,525,000	-	22,743,525,000	-

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

<i>Investments into associates</i>	<i>3,150,000,000</i>	<i>-</i>	<i>3,150,000,000</i>	<i>-</i>
Southern Hataphar Company Limited (ii)	700,000,000	-	700,000,000	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company (iii)	2,450,000,000	-	2,450,000,000	-
Total (*)	25,893,525,000	-	25,893,525,000	-

Summary of operations in subsidiaries, associates:

(i) According to the 9th amended Business Registration Certificate dated April 15, 2016, the Company invested in Hatay Pharmaceutical and Medical Equipment Joint Stock Company with a value of VND 20,857,750,000, equivalent to 50.63% of the charter capital. At the end of the accounting period, the Company invested VND 20,857,750,000, equivalent to 50.63% of the charter capital.

(ii) According to the 7th amended Business Registration Certificate dated June 15, 2017, the Company invested in Southern Hataphar Company Limited with a value of VND 700,000,000, equivalent to 48.28% of the charter capital. At the end of the accounting period, the Company invested VND 700,000,000, equivalent to 48.28% of the charter capital.

(iii) According to the 2nd amended Business Registration Certificate dated June 20, 2023, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company with a value of VND 4,900,000,000, equivalent to 49% of the charter capital. During the period, the Company received stock dividends in the amount of 490,000 shares. At the end of the accounting period, the Company held 49% of the charter capital, equivalent to 980,000 shares of Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company (the beginning of the year was 490,000 shares, equivalent to 49% of the charter capital). According to the 3rd amended Business Registration Certificate dated June 11, 2025, the Company invested in Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company with a value of VND 9,800,000,000, equivalent to 49% of the charter capital.

Subsidiaries and associates are operating normally, with no major changes compared to last year.

Significant transactions between the Company and its subsidiaries and associated companies are present detailed in note VII.2.

(*) As at June 30, 2025, all of the above investments undetermined fair value due to do not have market prices or insufficient information necessary to assess fair value. The fair value of these investments may differ from their book value.

3. Trade accounts receivable

	30/6/2025		01/01/2025	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short-term	130,634,237,671	(3,524,000,723)	130,260,462,165	(3,311,151,234)
<i>- In which, some trade accounts receivable have large balances:</i>				
Thanh Vinh Pharmaceutical and Medical Supplies Joint Stock Company	2,440,807,940	-	1,309,526,370	-
Thuan Anh Pharmaceutical Company Limited	6,368,579,175	-	9,454,374,467	-
Phap Au Medicine and Pharmacy Joint Stock	867,883,084	-	1,450,206,484	-
Duc Tam Company Limited	1,235,312,186	-	868,896,298	-

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Vinh Gia Pharmaceutical Joint Stock Company	2,830,381,947	-	2,869,454,757	-
Truong Huy Company Limited	2,984,786,591	-	4,119,196,070	-
Hanh Ha Pharmaceutical Joint Stock Company	2,449,720,007	-	4,821,708,418	-
Vinaplant Pharmaceutical Joint Stock Company	6,927,272,979	-	5,131,474,842	-
Stabled Pharmaceutical Company Limited	2,533,617,628	-	4,380,639,034	-
Kim Long Investment Joint Stock Company	1,565,371,425	-	2,879,529,852	-
Thu Duc City Hospital	1,901,125,000	(1,798,460,000)	1,992,665,000	(1,722,334,000)
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	15,692,402,643	-	13,644,284,878	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	23,883,117,026	-	61,003,338,292	-
T&T Equipment Joint Stock Company	8,741,969,164	-	837,406,953	-
Life Pharmaceutical and Medical Equipment Joint Stock Company	12,587,911,990	-	-	-
California USA Pharmaceutical Co., Ltd	10,406,491,208	-	-	-

*b) Trade accounts receivable from related parties: Details are presented in Note VIII.2***4. Advances to suppliers**

	30/6/2025 VND	01/01/2025 VND
<i>a) Short-term</i>	67,261,365,621	58,456,628,765
<i>- In which, some advances to suppliers have large balances:</i>		
Panpharma GMBH	-	13,154,807,906
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	3,136,254,281	1,709,103,940
Eskayef Bangladet .,ltd	-	3,698,936,177
XL Laboratories PVT.,LTD	2,900,559,780	18,931,343,957
Bliss Pharma distribution and consul Tancy corp	18,544,678,160	2,364,270,000
Tien Tuan Pharmaceutical Machinery Manufacturing Company Limited	80,477,280	359,276,040
Delta Pharma Ltd	32,298,302,671	5,145,850,347
Pharmametics products a division of max Biocare	518,960,000	3,043,217,797
Thang Long Elevator Equipment Group Company Limited	-	824,800,000

b) Advances to suppliers are r elated parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

5. Other receivables

	30/6/2025 VND		01/01/2025 VND	
	Amount	Provision	Amount	Provision
Short-term				
<i>Other receivables</i>	1,722,027,070	-	2,043,468,641	-
Accruals of interest income	1,677,369,841	-	1,979,397,260	-
<i>Vietnam Joint Stock</i>	1,361,753,425	-	1,979,397,260	-
<i>Commercial Bank for</i>				
<i>Industry and Trade - Thanh</i>				
<i>An Branch</i>				
<i>Vietnam Asia Commercial</i>	315,616,416	-	-	-
<i>Joint Stock Bank - Ha Dong</i>				
<i>Others</i>	44,657,229	-	64,071,381	-
<i>Advances</i>	304,986,411	-	417,855,111	-
Hoang Thi Minh Nguyet	-	-	300,000,000	-
Nguyen Van Phuc	100,000,000	-	-	-
Others	204,986,411	-	117,855,111	-
<i>Mortgages, collaterals</i>	6,407,042,500	-	6,407,042,500	-
Hoa Lac Hi-Tech Park	6,407,042,500	-	6,407,042,500	-
Management Board (*)				
Total	8,434,055,981	-	8,868,366,252	-

(*) The deposit for Hoa Lac High-Tech Park Management Board to ensure the implementation of the investment project "Hataphar High-Tech Pharmaceutical Factory" is agreed upon in the Investment Project Implementation Guarantee Deposit Agreement No. 06/TTKQ dated 27/11/2020.

6. Bad debts

	30/6/2025 VND		01/01/2025 VND	
	Cost	Recoverable value	Cost	Recoverable value
Total amount of receivables past due but impaired				
Thu Duc City Hospital	1,901,125,000	102,665,000	1,866,065,000	143,731,000
Others	2,257,310,216	531,769,493	1,678,633,431	89,816,197
Total	4,158,435,216	634,434,493	3,544,698,431	233,547,197

7. Inventories

	30/6/2025 VND		01/01/2025 VND	
	Cost	Provision	Cost	Provision
Good in transit	25,375,807,991	-	65,940,100,079	-
Raw materials	94,576,318,541	-	92,390,339,708	-
Tools, instruments	66,353,605	-	314,745,427	-
Work in progress	-	-	1,838,766,875	-
Finished good	37,015,908,417	(1,961,049,751)	43,390,614,449	(1,961,049,751)
Merchandise	372,003,788,490	-	298,362,438,653	-
Total	529,038,177,044	(1,961,049,751)	502,237,005,191	(1,961,049,751)

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

8. Increases, decreases of intangible fixed assets

Items	Unit: VND		
	Accounting software	Land use rights	Total
Historical cost			
Balance as at January 01, 2025	650,000,000	1,376,660,000	2,026,660,000
Balance as at June 30, 2025	650,000,000	1,376,660,000	2,026,660,000
Accumulated amortization			
Balance as at January 01, 2025	650,000,000	-	650,000,000
Balance as at June 30, 2025	650,000,000	-	650,000,000
Net book value			
As at January 01, 2025	-	1,376,660,000	1,376,660,000
As at June 30, 2025	-	1,376,660,000	1,376,660,000

Historical cost of fixed assets which has been fully depreciated as at June 30, 2025: VND 650,000,000 (As at January 01, 2025: VND 650,000,000)

9. Work in progress

	30/6/2025 VND	01/01/2025 VND
Fixed asset purchases	-	-
Cost of research	11,715,094,208	6,912,583,752
Hataphar High-Tech Pharmaceutical Factory Project (*)	800,058,857,577	783,197,217,350
Total	811,773,951,785	790,109,801,102

(*) The investment project is implemented according to the Minutes of the Extraordinary Shareholders' Meeting No. 855/BB-DHT dated August 26, 2020 and the Resolution of the Extraordinary Shareholders' Meeting No. 856/NQ-DHT dated August 26, 2020 on approving the Project: "Hataphar High-Tech Pharmaceutical Factory" and the Resolution of the Board of Directors No. 546/NQ-DHT dated June 28, 2024 approving the total estimated budget of the Hataphar High-Tech Pharmaceutical Factory to increase to VND 868 billion. In which, the capitalized loan interest on the Project accumulated to June 30, 2025: VND 24,494,318,831 (As at January 01, 2025: VND 19,780,939,500).

10. Prepayment

	30/6/2025 VND	01/01/2025 VND
Long-term		
Tools and supplies awaiting for allocation	1,632,980,550	1,378,549,737
Factory repair costs	2,721,010,617	3,228,447,845
Others	17,708,331	23,958,333
Total	4,371,699,498	4,630,955,915

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 10A Quang Trung, Ha Dong ward, Hanoi, Vietnam

INTERIM SEPARATE FINANCIAL STATEMENTS

For the period from January 01, 2025 to June 30, 2025

Form B 09a - DN

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

11. Increases, decreases of tangible fixed assets

Items	Buildings and architectural objects	Machinery and equipment	Means of transportation	Managerial equipment, tools	Other fixed assets	Total
Historical cost						
Balance as at January 01, 2025	148,548,688,718	226,459,757,362	10,057,895,478	4,663,246,467	439,282,500	390,168,870,525
Purchase in the period	-	4,329,456,102	1,071,875,548	-	-	5,401,331,650
Completed from construction in progress	3,046,101,345	-	-	-	-	3,046,101,345
Disposals	-	(671,688,703)	(860,090,900)	(880,434,524)	-	(2,412,214,127)
Balance as at June 30, 2025	151,594,790,063	230,117,524,761	10,269,680,126	3,782,811,943	439,282,500	396,204,089,393
Accumulated depreciation						
Balance as at January 01, 2025	85,053,425,626	124,536,441,980	5,682,389,665	4,474,850,023	439,282,500	220,186,389,794
Charge for the period	3,160,649,868	7,362,229,099	327,524,282	23,552,450	-	10,873,955,699
Disposals	-	(671,688,703)	(860,090,900)	(880,434,524)	-	(2,412,214,127)
Balance as at June 30, 2025	88,214,075,494	131,226,982,376	5,149,823,047	3,617,967,949	439,282,500	228,648,131,366
Net book value						
As at January 01, 2025	63,495,263,092	101,923,315,382	4,375,505,813	188,396,444	-	169,982,480,731
As at June 30, 2025	63,380,714,569	98,890,542,385	5,119,857,079	164,843,994	-	167,555,958,027

Historical cost of fixed assets which has been fully depreciated but still in use as at June 30, 2025: VND 144,180,396,773 (As at December 31, 2024: VND 147,065,273,043)

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

12. Trade accounts payable

	30/6/2025		01/01/2025	
	VND		VND	
	Historical cost	Amount able to be paid off	Historical cost	Amount able to be paid off
a) Short-term	297,064,872,740	297,064,872,740	223,336,294,360	223,336,294,360
<i>- In which, some trade accounts payable have large balances:</i>				
Dong Au Trading and Production Company Limited	2,666,223,433	2,666,223,433	3,907,753,067	3,907,753,067
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	5,843,596,670	5,843,596,670	9,240,668,628	9,240,668,628
KPC Pharmaceuticals, Inc	19,295,404,404	19,295,404,404	18,745,888,869	18,745,888,869
Laboratorio Italiano Biochimico Farmaceutico Lisa pharma S.P.A	-	-	24,197,333,026	24,197,333,026
Inbiotech l.t.d	7,240,797,600	7,240,797,600	9,194,736,030	9,194,736,030
XL Laboratories PVT.,Ltd	93,938,509,512	93,938,509,512	16,837,250,486	16,837,250,486
Pharmaunity Co.,Ltd	33,464,433,496	33,464,433,496	33,987,410,018	33,987,410,018
Concord Biotech Limited	19,981,298,760	19,981,298,760	20,490,547,797	20,490,547,797
Saifen Drugs (Hong Kong) Ltd	16,850,808,182	16,850,808,182	7,621,817,561	7,621,817,561
Gracure Pharmaceuticals Limited	10,128,675,725	10,128,675,725	12,949,962,228	12,949,962,228

b) Trade accounts payable as related parties: Details are presented in Note VIII.2

13. Advances from customers

	30/6/2025	01/01/2025
	VND	VND
a) Short-term	150,088,373,148	130,401,909,109
<i>- In which, some advances from customers have large balances:</i>		
T&T Equipment Joint Stock Company	-	6,556,194,866
T&T Pharmaceutical and Trading Joint Stock Company	1,787,705,420	2,779,357,780
Tan Truong Sinh Trading Joint Stock Company	-	2,911,479,920
Vistar Trading Development and Investment Joint Stock Company	2,294,027,221	820,670,220
Bao Ngan Pharmaceutical Company Limited	-	10,735,707,200
Dong Do Pharmaceutical Company Limited	17,724,547,315	31,178,516,478
TB Vietnam Pharmaceutical Trading Company Limited	30,592,944,421	24,495,082,359
Vietlife Pharmaceutical Joint Stock Company	1,603,308,000	3,722,000,000
Lam An Pharmaceutical Trading Company Limited	13,000,000,000	11,700,000,000
Tan Dai Cat Pharmaceutical Company Limited	2,900,000,000	3,409,598,360
Danh Minh Pharmaceutical Joint Stock Company	6,662,995,840	-
1A Vietnam Pharmaceutical Company Limited	10,420,000,000	-
Dai Thuy Pharmaceutical and Trading Joint Stock Company	8,928,359,550	-
Thuan An Phat Pharmaceutical Joint Stock Company	5,543,367,000	-

b) Advances from customers are related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)*(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)***14. Taxes and payables to the State budget**

Unit: VND

Items	01/01/2025	Amounts payable in the period	Amounts paid in the period	30/6/2025
a) Payables				
Value added tax for domestic goods	6,639,831	124,054,476	31,985,518	98,708,789
Value added tax for import goods	-	39,551,558,694	39,551,558,694	-
Corporate income tax	4,634,215,172	6,817,097,733	8,736,787,583	2,714,525,322
Personal income tax	980,002,093	1,930,032,183	2,778,899,868	131,134,408
Natural resource tax	-	11,563,200	11,563,200	-
Land rental fee	-	2,401,930,948	2,401,930,948	-
Business license fee	-	20,000,000	20,000,000	-
Total	5,620,857,096	50,856,237,234	53,532,725,811	2,944,368,519
b) Receivables				
Value added tax for domestic goods	622,855,829	-	-	622,855,829
Import and export duties	8,413,385	6,349,325,741	6,340,912,356	-
Total	631,269,214	6,349,325,741	6,340,912,356	622,855,829

15. Accrued expenses

	30/6/2025 VND	01/01/2025 VND
Short-term		
Accrued interest payable	116,731,054	162,743,579
Accrued expenses of the Company's 60th anniversary	2,009,800,025	-
Total	2,126,531,079	162,743,579

16. Unearned revenue

	30/6/2025 VND	01/01/2025 VND
Short-term		
Unearned revenue from leases	1,497,365,896	909,298,387
Total	1,497,365,896	909,298,387

17. Other payables

	30/6/2025 VND	01/01/2025 VND
a) Short-term	287,431,378	72,107,933
Insurances	-	28,437,874
Others	287,431,378	43,670,059
b) Long-term	4,367,300,000	4,403,300,000
Get escrow, term deposits	4,367,300,000	4,403,300,000
Total	4,654,731,378	4,475,407,933

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

18. Loans and obligations under finance lease

	30/6/2025		In the period		01/01/2025		Unit: VND
	Amount	Amount able to be paid off	Increase	Decrease	Amount	Amount able to be paid off	
a) Short-term	325,692,156,052	325,692,156,052	381,263,054,367	428,844,873,182	373,273,974,867	373,273,974,867	
a1) Short-term borrowing	311,847,448,127	311,847,448,127	381,263,054,367	428,844,873,182	359,429,266,942	359,429,266,942	
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch (1)	85,860,521,855	85,860,521,855	93,588,379,871	152,166,320,698	144,438,462,682	144,438,462,682	
Joint Stock Commercial Bank For Foreign Trade Of Vietnam - West Hanoi Branch (2)	65,393,732,420	65,393,732,420	113,349,658,999	148,040,423,238	100,084,496,659	100,084,496,659	
Shinhan Bank Vietnam Limited - Hanoi Branch (3)	50,513,709,028	50,513,709,028	61,288,812,401	66,372,156,289	55,597,052,916	55,597,052,916	
Joint stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch (4)	61,213,812,532	61,213,812,532	87,584,862,290	43,549,277,420	17,178,227,662	17,178,227,662	
Individuals (5)	48,865,672,292	48,865,672,292	25,451,340,806	18,716,695,537	42,131,027,023	42,131,027,023	
a2) Long-term borrowings on due date	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925	
MUFG Bank, Ltd., - Hanoi Branch (6)	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925	
b) Long-term borrowing	96,912,955,472	96,912,955,472	-	-	96,912,955,472	96,912,955,472	
MUFG Bank, Ltd., - Hanoi Branch (6)	96,912,955,472	96,912,955,472	-	-	96,912,955,472	96,912,955,472	
Total	422,605,111,524	422,605,111,524	381,263,054,367	428,844,873,182	470,186,930,339	470,186,930,339	

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

(1) Credit Contract No. 2209/2024-HĐCVHM/NHCT320-HATAPHAR dated September 23, 2024, loan limit of VND 150 billion (including debts adjusted by Credit Contract No. 2209/2023-HĐCVHM/NHCT320-HATAPHAR dated September 22, 2023), loan purpose: supplementing working capital for production and business activities; loan interest rate is the interest rate stated on each indebtedness certificate and is valid from the time of disbursement until the interest rate is adjusted on the twenty-fifth (25th) (or the previous business day if the twenty-fifth (25th) is not a business day); the loan term of each debt is stated on the indebtedness certificate but not exceeding 5 months/indebtedness certificate from the time of loan disbursement; Limit maintenance period until September 23, 2025; unsecured loan.

(2) Loan contract under the limit No. 04/25/QLN/HM/VCBTHN dated February 06, 2025 attached to the credit contract No. 04/25/QLN/CTD/VCBTHN dated February 06, 2025, the contract for issuing letters of credit under the limit No. 04/25/QLN/HMLC/VCBTHN dated February 06, 2025, the credit guarantee agreement under the limit No. 04/25/QLN/HMBL/VCBTHN dated February 06, 2025 and the Amended and supplemented contract dated April 04, 2025, the loan limit is VND 200 billion (including the limit of the loan contract under the limit No. 37/23/QLN/HM/VCBTHN dated October 17, 2023), the purpose of the loan is to finance short-term borrowing needs. legal, reasonable, valid to serve the production and business activities of the Customer but does not include short-term needs to serve fixed asset investment activities, interest rates are specifically regulated for each debt receipt; the loan term of each debt is a maximum of 05 months; the credit term is 12 months from the date of signing the contract or until February 19, 2026, whichever comes first; the loan is unsecured.

(3) Credit contract No. 130002065517 dated August 16, 2019 and extension - amendment supplement No. 130002065517/10 dated September 05, 2024 extending the limit until August 15, 2025, the loan limit is VND 80 billion, the purpose of the loan is to supplement working capital for production and business activities; loan interest rate: in case of fixed interest rate for the loan, the fixed interest rate is applied throughout the loan term according to the interest rate specified on the Drawdown Applications and Acknowledgement of Debt of each loan, in case of adjusted interest rate: apply the 3-month MFC reference interest rate plus (+) Margin of 0.74%/year and adjust every 3 months throughout the loan term; The term of each credit is within the limit specified in each indebtedness certificate but does not exceed 03 months/contract; the credit term is 05 years from the date of signing the contract, the loan is unsecured.

(4) Credit limit contract No. 01/2025/177578/HDTD dated June 10, 2025; regular credit limit with a maximum amount of VND 200 billion; loan purpose: supplementing working capital, guarantee, opening L/C; interest rate is determined in each specific contract according to the Bank's interest rate regime in each period; credit limit period is 12 months from the date of signing this Contract; the loan has no collateral.

(5) Individuals loans according to each loan contract, for the purpose of serving the Company's production and business activities; loan term of less than 12 months; interest rate from 0.033%/month to 0.4%/month.

(6) Long-term credit contract No. FL/053/22 dated August 02, 2022, amendment agreement No. 02 dated January 17, 2023, amendment agreement No. 03 dated December 27, 2023 for Credit Contract No. FL/053/22 dated August 02, 2022, credit limit not exceeding VND 235 billion, loan term until December 31, 2032. Loan purpose is for Fixed Asset Investment/Factory Construction and not for any other purpose. The specific interest rate for the first interest period stated in the Drawdown Applications which forms an integral part of such requests shall be binding on both parties from the time the Bank and the Customer agree on such interest rate (whether orally or otherwise), the specific interest rate and other terms of subsequent drawdown shall be evidenced in a "Loan Notice" sent by the Bank to the Customer. In relation to each drawdown made: before the last business day of December 2022, the first interest period shall commence on (and include) the drawdown date of such drawdown and end on (but not include) the last business day of December 2022; after the last business day of December 2022, the first interest period shall commence on (and include) the drawdown date of such drawdown and end on (but not include) the last business day of December nearest; each subsequent Interest period shall commence on (and including) the last day of the preceding interest period and end on (but not including) the last business day of each of March, June, September and December nearest, each subsequent interest period shall commence on (and including) the last day of the preceding interest period and end on (but not including) the last business day of each of March, June, September and December. The Loan is secured by a letter of guarantee issued by Aska Pharmaceutical Holdings Co., Ltd on August 02, 2022. The first repayment relate with a Drawdown shall be made on the last business day of December 2025, with subsequent repayments being made every 12 months.

c) Loans and obligations under finance lease are related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

19. Owner's equity		Unit: VND				
a) Movement in owner's equity						
Items	Owner's contributed capital	Share premium	Other capital	Treasury stock	Retained earnings	Total
Balance as at 01/01/2024	823,417,730,000	96,320,000,000	24,375,893,101	(15,130,000)	79,313,204,892	1,023,411,697,993
Profit in the previous year	-	-	-	-	67,563,189,336	67,563,189,336
Dividends of 2023	-	-	-	-	(41,170,130,000)	(41,170,130,000)
Advances payment dividends of 2024	-	-	-	-	(41,170,130,000)	(41,170,130,000)
Balance as at 31/12/2024	823,417,730,000	96,320,000,000	24,375,893,101	(15,130,000)	64,536,134,228	1,008,634,627,329
Profit in this period	-	-	-	-	28,612,987,213	28,612,987,213
Balance as at 30/6/2025	823,417,730,000	96,320,000,000	24,375,893,101	(15,130,000)	93,149,121,441	1,037,247,614,542

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)*(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)***b) Details of owner's equity**

	30/6/2025	01/01/2025
	VND	VND
Hanoi City Development Investment Fund	30,978,660,000	30,978,660,000
ASKA Pharmaceutical Co.,Ltd	329,752,390,000	321,810,390,000
Le Van Lo	46,199,910,000	46,199,910,000
Ngo Van Chinh	20,178,110,000	20,178,110,000
Hoang Van Tue	32,866,560,000	32,866,560,000
Le Viet Linh	52,219,860,000	52,219,860,000
Nguyen Thi Minh Hau	1,568,280,000	1,568,280,000
Le Anh Trung	30,653,390,000	30,653,390,000
Le Xuan Thang	32,004,810,000	32,004,810,000
Ngo Tuan Viet	5,000,000,000	5,000,000,000
Others	241,995,760,000	249,937,760,000
Total	823,417,730,000	823,417,730,000

c) Capital transactions with owners, dividend distribution and shared profit

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Owner's contributed capital		
Contribution at the beginning of the period	823,417,730,000	823,417,730,000
Increase in the period	-	-
Contribution at the end of period	823,417,730,000	823,417,730,000
Paid dividend, shared profit	-	41,170,130,000

d) Shares

	30/6/2025	01/01/2025
	Shares	Shares
Number of shares registered for issue	82,341,773	82,341,773
Number of shares issued to the public	82,341,773	82,341,773
- Ordinary shares	82,341,773	82,341,773
Number of shares buyback	1,513	1,513
- Ordinary shares	1,513	1,513
Number of outstanding shares in circulation	82,340,260	82,340,260
- Ordinary shares	82,340,260	82,340,260

An ordinary share has par value of VND 10,000

e) Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares:

- Dividends declared on preferred stock: none

Unrecorded cumulative preferred stock dividends: none

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

f) Funds of the Company

Unit: VND

Items	01/01/2025	Increase	Decrease	30/6/2025
Investment and Development fund	8,963,148,976	-	-	8,963,148,976
Total	8,963,148,976	-	-	8,963,148,976

20. Off Interim Separate Balance Sheet items**Foreign currencies**

	30/6/2025	01/01/2025
US Dollar (USD)	4,122.55	8,883.21
Euro (EUR)	365.76	311.93

VI. Additional information for items presented in Interim Separate Income Statement**1. Gross revenue from goods sold and services rendered**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Sales		
Sales of finished good	265,730,014,278	281,865,291,227
Sales of merchandise	749,873,376,350	652,318,997,036
Total	1,015,603,390,628	934,184,288,263

b) Sales with related parties: Details are presented in Note VIII.2**2. Deductions**

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Sales return	-	136,570,760
Total	-	136,570,760

3. Net revenue from goods sold and services rendered

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Net revenue		
Sales of finished good	265,730,014,278	281,728,720,467
Sales of merchandise	749,873,376,350	652,318,997,036
Total	1,015,603,390,628	934,047,717,503

b) Net revenue with related parties: Details are presented in Note VIII.2

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

4. Cost of goods sold

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Cost of finished goods sold	182,242,619,588	208,369,420,385
Cost of merchandise sold	732,963,198,401	634,189,814,766
Inventory handling costs	100,983,755	-
Total	915,306,801,744	842,559,235,151

5. Financial income

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
a) Financial income		
Interest income	2,950,087,761	4,441,607,082
Dividends, profits shared	2,022,887,500	6,194,437,500
Foreign exchange gain in the period	694,108,863	208,464,190
Interest on deferred payment, payment discounts	7,250,834,138	4,058,212,278
Others	-	171,614,716
Total	12,917,918,262	15,074,335,766

b) Financial income with related parties: Details are presented in Note VIII.2

6. Financial expenses

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
a) Financial expenses incurred in the period	13,245,813,064	11,625,076,116
Interest expenses	7,127,225,787	6,415,974,512
Foreign exchange loss in the period	818,860,074	3,263,802,929
Loss from exchange rate difference due to revaluation at the period end	5,299,727,203	1,192,027,911
Others	-	753,270,764
Total	13,245,813,064	11,625,076,116

b) Financial expenses with related parties: Details are presented in Note VIII.2

7. Other income

	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
	VND	VND
Gain from disposals of fixed assets	100,000,000	-
Labor leasing income	48,613,865	301,144,097
Leases income	7,002,215,655	5,951,646,565
Others	293,678,870	842,799,576
Total	7,444,508,390	7,095,590,238

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

8. Other expenses

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Back taxes, late payment penalty	95,270,996	3,616,523
VAT is not refundable	534,173,474	-
Others	19	-
Total	629,444,489	3,616,523

9. Selling expenses and general administration expenses

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Selling expenses incurred in the period	13,939,566,132	14,301,659,202
Staff cost	7,576,125,608	8,531,600,927
Materials, packaging expenses	220,082,292	230,005,178
Equipment expenses	52,131,060	61,036,840
Depreciation and amortization	300,477,432	240,629,274
External services expenses	1,427,234,974	458,385,946
Other expenses in cash	4,363,514,766	4,780,001,037
b) General administration expenses incurred in the period	57,504,913,706	46,535,385,350
Staff cost	24,467,311,240	16,703,306,940
Material cost management	1,791,987,821	1,996,462,385
Office equipment expenses	4,861,630,843	2,551,099,025
Depreciation and amortization	1,191,917,672	1,036,392,495
Taxes, fees and charges	1,427,508,634	1,817,214,394
Provision expenses	303,656,290	1,834,651,660
External services expenses	8,353,042,002	7,063,364,429
Other expenses in cash	15,107,859,204	13,532,894,022
c) Deduction from general administration expenses	(90,806,801)	(181,748,210)
Reversal of provisions for doubtful debts	(90,806,801)	(181,748,210)

10. Operating cost by nature

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Raw materials and consumables	151,066,661,550	173,757,006,301
Staff cost	44,069,744,456	40,472,485,305
Depreciation and amortization	10,873,955,699	8,272,662,442
External services expenses	16,268,279,854	12,016,103,356
Other expenses in cash	29,845,824,181	28,177,729,420
Total	252,124,465,740	262,695,986,824

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

11. Current corporate income tax expenses

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
Accounting profit before corporate income tax	35,430,084,946	41,374,419,375
Incomes exempted from corporate income tax	(2,022,887,500)	(6,194,437,500)
Corporate income tax non-deductible expense	678,291,218	52,463,252
Thu nhập tính thuế thu nhập doanh nghiệp	34,085,488,664	35,232,445,127
Current corporate income tax rate	20%	20%
Total current corporate income tax expense	6,817,097,733	7,046,489,025

12. Basic earning per share

Basic earning per share is not presented on these Interim Separate Financial Statements but it will be presented on the Interim Consolidated Financial Statements for the period from January 01, 2025 to June 30, 2025 under guidelines in Vietnamese Accounting Standard No. 30 - Basic earning per share.

VII. Additional information for items presented in the Interim Separate Cash Flow Statement

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
1. Proceeds of borrowings in the period		
Proceeds of borrowings under regular agreements	381,263,054,367	324,607,532,614
2. Repayment of borrowings in the period		
Repayment of borrowing under regular agreements	428,844,873,182	452,036,704,645

VIII Other information

1. Subsequent events after the Balance Sheet date

According to Resolution of the Board of Directors of Hatay Pharmaceutical Joint Stock Company No. 566/NQ-DHT dated July 24, 2025, the Board of Directors approved the organization of an extraordinary General Meeting of Shareholders in 2025 to approve the issuance of bonus shares to existing shareholders at a rate of 10% from the Company's share premium and profits.

The Board of Management confirms that, according to the Board of Management, in all material respects, apart from the above-mentioned event, there are no unusual events arising after the balance sheet date which affects the financial position and operation of the Company that needed to be adjusted or presented on the Interim Separate Financial Statements for the period from January 01, 2025 to June 30, 2025.

2. Transactions and balances with related parties

Related parties of the Company include: Key members, individuals who are related to key members and other related parties.

List of related parties:

Related parties

Hatay Pharmaceutical and Medical Equipment Joint Stock Company
Southern Hataphar Company Limited
Vietnam Hataphar Healthcare High Technology Pharmaceutical
Joint Stock Company

Relationship

Subsidiary
Affiliated Company
Affiliated Company

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Mr. Le Van Lo	Chairman
Mr. Le Xuan Thang	General Director, Member of BOD
Mr. Nguyen Ba Lai	Deputy General Director
Mr. Ngo Tuan Viet	Deputy General Director
Mr. Hoang Van Tue	Member of BOD
Mr. Le Anh Trung	Vice Chairman, Deputy General Director
Ms. Le Viet Linh	Member of BOD, Deputy General Director
Mr. Hiroyasu Nishioka	Member of BOD
Mr. Keisuke Oshio	Member of BOD
Mr. Ngo Van Chinh	Head of Board of Supervisors
Mr. Nguyen Ha De	Member of Board of Supervisors
Mr. Kazuhizo Chiku	Member of Board of Supervisors (Appointed on April 14, 2025)

2.1. During the period, the Company has entered into its significant transactions with related parties:

	From 01/01/2025 to 30/6/2025 VND	From 01/01/2024 to 30/6/2024 VND
a) Purchase		
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	2,855,031,980	2,532,057,034
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	37,602,527,438	40,100,874,517
b) Sales		
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	8,965,277,918	7,492,410,047
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	102,463,763,359	121,998,874,689
c) Financial income (dividend received)		
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	1,042,887,500	5,214,437,500
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	980,000,000	980,000,000
d) Interest expenses		
Mr. Le Van Lo	508,597,522	631,311,887
Mr. Nguyen Ba Lai	71,285,488	81,794,674
Mr. Le Xuan Thang	-	286,985,790
Mr. Hoang Van Tue	29,594,844	194,211,654
Mr. Le Anh Trung	10,360,475	272,882,791
Ms. Le Viet Linh	-	333,423,300
Mr. Ngo Van Chinh	-	119,234,388

2.2. Balances with related parties

	30/6/2025 VND	01/01/2025 VND
a) Trade accounts receivable		
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	15,692,402,643	13,644,284,878

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	23,883,117,026	61,003,338,292
b) Advances to suppliers		
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	3,136,254,281	1,709,103,940
c) Trade accounts payable		
Hatay Pharmaceutical and Medical Equipment Joint Stock Company	69,886,999	766,490,056
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company	5,843,596,670	9,240,668,628
d) Loans and obligations under finance lease		
Mr. Le Van Lo	21,780,220,372	7,900,585,989
Mr. Nguyen Ba Lai	3,000,000,000	2,000,000,000
Mr. Hoang Van Tue	989,872,000	980,400,000
Mr. Le Anh Trung	429,301,455	429,301,455

2.3. Income of key management members

Income entitled of key management members in the year are as follows:

Name	Position	From 01/01/2025 to 30/6/2025	From 01/01/2024 to 30/6/2024
		VND	VND
Le Van Lo	Chairman	918,732,000	783,331,100
Hiroyasu Nishioka	Member of BOD	-	-
Keisuke Oshio	Member of BOD	-	-
Le Xuan Thang	General Director, Member of BOD	843,371,760	715,855,400
Nguyen Ba Lai	Deputy General Director	679,952,200	638,022,400
Le Anh Trung	Deputy General Director Vice Chairman	791,024,100	676,204,400
Le Viet Linh	Deputy General Director Member of BOD	792,825,660	672,685,300
Ngo Tuan Viet	Deputy General Director	544,312,300	162,088,100
Hoang Van Tue	Chief Accountant, Member of BOD	716,481,960	604,531,200
Ngo Van Chinh	Head of Board of Supervisors	680,783,400	572,401,400
Dang Dinh Du	Member of Board of Supervisors (Retirement and resignation from September 01, 2024)	-	345,953,500
Nguyen Ha De	Member of Board of Supervisors	256,591,400	221,832,100
Kazuhizo Chiku	Member of Board of Supervisors (Appointed on April 14, 2025)	-	-
Total		6,224,074,780	5,392,904,900

NOTES TO THE INTERIM SEPARATE FINANCIAL STATEMENTS (continued)

(Notes are an integral part of and they shall be read in conjunction with such enclosed Interim Separate Financial Statements)

3. Comparative information

Representing data are taken from Interim Separate Financial Statements for the period from January 01, 2024 to June 30, 2024 and Separate Financial Statements for the fiscal year ended December 31, 2024 of Hatay Pharmaceutical Joint Stock Company which were reviewed and audited by Vietnam Auditing and Evaluation Co., Ltd.

Hanoi, August 19, 2025

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by



Nguyen Thi Bich Ngoc

Chief Accountant



Hoang Van Tue

General Director



Le Xuan Thang

